BRPI1013649A2 - anticorpo monoclonal humano que se liga especificamente a vcam-1 e composição para o tratamento de uma doença inflamatória ou câncer compreende o mesmo - Google Patents
anticorpo monoclonal humano que se liga especificamente a vcam-1 e composição para o tratamento de uma doença inflamatória ou câncer compreende o mesmoInfo
- Publication number
- BRPI1013649A2 BRPI1013649A2 BRPI1013649A BRPI1013649A BRPI1013649A2 BR PI1013649 A2 BRPI1013649 A2 BR PI1013649A2 BR PI1013649 A BRPI1013649 A BR PI1013649A BR PI1013649 A BRPI1013649 A BR PI1013649A BR PI1013649 A2 BRPI1013649 A2 BR PI1013649A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- composition
- monoclonal antibody
- same
- specifically binds
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2836—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70542—CD106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20090027721 | 2009-03-31 | ||
| PCT/KR2010/001988 WO2010114312A2 (en) | 2009-03-31 | 2010-03-31 | Human monoclonal antibody that specifically binds to vcam-1 and a composition for treating an inflammatory disease or a cancer comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1013649A2 true BRPI1013649A2 (pt) | 2019-09-24 |
Family
ID=42828861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1013649A BRPI1013649A2 (pt) | 2009-03-31 | 2010-03-31 | anticorpo monoclonal humano que se liga especificamente a vcam-1 e composição para o tratamento de uma doença inflamatória ou câncer compreende o mesmo |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8715670B2 (pt) |
| EP (1) | EP2414392A4 (pt) |
| JP (1) | JP5438819B2 (pt) |
| KR (1) | KR101238061B1 (pt) |
| CN (1) | CN102369216A (pt) |
| BR (1) | BRPI1013649A2 (pt) |
| WO (1) | WO2010114312A2 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8623368B2 (en) * | 2009-10-23 | 2014-01-07 | Hanwha Chemical Corporation | Human recombinant monoclonal antibody that specifically binds to VCAM-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells |
| JP5842630B2 (ja) * | 2011-03-16 | 2016-01-13 | 株式会社リコー | カルバゾール誘導体、及び半導体ナノ結晶 |
| GB201207155D0 (en) | 2012-04-24 | 2012-06-06 | Isis Innovation | Antibodies |
| DE102012208608A1 (de) * | 2012-05-23 | 2013-11-28 | Robert Bosch Gmbh | Verfahren zum Herstellen einer Elektrode für einen elektrochemischen Energiespeicher und Elektrode |
| AU2014306002B2 (en) * | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| KR102306493B1 (ko) | 2013-11-25 | 2021-09-28 | 씨젠 인크. | 접합을 위한 ｃｈｏ 세포 배양물로부터의 항체 제조 |
| US10947311B2 (en) | 2015-11-20 | 2021-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | VCAM-1 mediated methods and compositions for treating aging-associated impairments |
| CN116041522A (zh) * | 2023-02-28 | 2023-05-02 | 北京普恩光德生物科技开发有限公司 | 一种vcam-1单克隆抗体及制备方法和包含其的试剂盒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07506244A (ja) * | 1992-01-13 | 1995-07-13 | バイオゲン インコーポレイテッド | Ｖｃａｍ１の第４免疫グロブリン様ドメインを認識する抗体 |
| ES2319831T3 (es) | 1998-09-14 | 2009-05-12 | Board Of Regents, The University Of Texas System | Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina. |
| US7618630B2 (en) * | 1998-09-14 | 2009-11-17 | Board Of Regents, The University Of Texas System | Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| EP2021373A4 (en) * | 2006-05-31 | 2010-06-02 | Hanwa Chemical Corp | MONOCLONAL ANTIBODY VCAM-1 SPECIFIC |
| US20100172902A1 (en) * | 2006-05-31 | 2010-07-08 | Hanwha Chemical Corporation | Method for treating a vcam-1 mediated disease |
-
2010
- 2010-03-19 KR KR1020100024930A patent/KR101238061B1/ko not_active Expired - Fee Related
- 2010-03-31 JP JP2012503331A patent/JP5438819B2/ja not_active Expired - Fee Related
- 2010-03-31 CN CN2010800147716A patent/CN102369216A/zh active Pending
- 2010-03-31 US US13/262,212 patent/US8715670B2/en not_active Expired - Fee Related
- 2010-03-31 WO PCT/KR2010/001988 patent/WO2010114312A2/en not_active Ceased
- 2010-03-31 BR BRPI1013649A patent/BRPI1013649A2/pt not_active IP Right Cessation
- 2010-03-31 EP EP10759037A patent/EP2414392A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| KR101238061B1 (ko) | 2013-02-27 |
| US20120308574A1 (en) | 2012-12-06 |
| EP2414392A4 (en) | 2013-03-13 |
| JP2012522046A (ja) | 2012-09-20 |
| WO2010114312A3 (en) | 2011-03-31 |
| JP5438819B2 (ja) | 2014-03-12 |
| US8715670B2 (en) | 2014-05-06 |
| KR20100109394A (ko) | 2010-10-08 |
| CN102369216A (zh) | 2012-03-07 |
| WO2010114312A2 (en) | 2010-10-07 |
| EP2414392A2 (en) | 2012-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013649A2 (pt) | anticorpo monoclonal humano que se liga especificamente a vcam-1 e composição para o tratamento de uma doença inflamatória ou câncer compreende o mesmo | |
| CY2020021I2 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης | |
| PT2367561E (pt) | Composições e métodos para o tratamento da doença celíaca | |
| MA43576A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
| CL2014002750A1 (es) | Anticuerpo aislado o fragmento que se enlaza a un estado inactiva de un receptor her; composición farmacéutica que lo comprende; uso del anticuerpo para tratar cancer | |
| BR112013004056B8 (pt) | Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende | |
| CL2014000590A1 (es) | Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia. | |
| CR20120577A (es) | Anticuerpos hacia gdf8 humano | |
| PT2361936T (pt) | Molécula que se liga a antigénio e utilizações desta | |
| BRPI0918178A2 (pt) | anticorpos monoclonais para tratamento de câncer | |
| BRPI0820530A2 (pt) | Anticorpos monoclonais que se ligam ao hgm-csf e composições medicinais compreendendo os mesmos | |
| BRPI0719202A2 (pt) | Diagnóstico e tratamento de câncer usando anticorpo antiereg | |
| BRPI1008692A2 (pt) | moléculas de anticorpos tendo especificidade para ox40 humano. | |
| BRPI0915928A2 (pt) | composições e métodos de uso para anticorpos terapêuticos | |
| BRPI0916862A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias | |
| PT2435432E (pt) | Agentes indutores de apoptose para o tratamento de cancro e doenças imunes e autoimunes | |
| BRPI1015569A2 (pt) | compostos úteis para o tratamento de doenças degenerativas e inflamatórias. | |
| BRPI1014759A2 (pt) | composto útil para o tratamento de doenças degenerativas e inflamatórias | |
| BRPI0921805A2 (pt) | anticorpos que especificamente bloqueiam a atividade biológica de um antígeno de tumor | |
| BRPI0814644A2 (pt) | Anticorpos para cd200 e usos destes na inibição de respostas imunes. | |
| BRPI1010540A2 (pt) | "anticorpos especéficos para dkk-1 e seus usos" | |
| EP2525813A4 (en) | ANTIBODIES TO ILT5 AND ILT5 BINDING ANTIBODY FRAGMENTS | |
| PT2651975T (pt) | Anticorpo monoclonal humano com especificidade para a proteína do vírus do dengue de seroptipo 1 e suas utilizações | |
| EP2385114A4 (en) | CANCER TREATMENT DIAGNOSIS WITH ANTI-TM4SF20 ANTIBODY | |
| BR112012002265A2 (pt) | composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |